Study On Biological Characteristics Of Cord Blood CD133+ Hematopoietic Stem/Progenitor Cell And Preparation Of Anti-CD133 MAb

Effective selection of hematopoietic stem and progenitor cells is important, both for clinical transplantation therapy and basic research. Over the past decade, antibodies to CD34 have been commonly used as a marker to select hematopoietic stem and progenitor cells. However, isolated CD34+ cells are heterogeneous, and the stem cell content is a small fraction of the total CD34+ population. There is increasing evidence that human CD34- hematopoietic stem cells may exist and that such cells may be more immature than CD34+ stem cells. Consequently, alternative selection markers to CD34 antigen would be very useful. A novel antigen, CD133, is a strong candidate for this purpose. Further studies should give information concerning the significance of this subset. CD133 provides an alternative to CD34 for the selection and characterization of cells necessary for studies of ex vivo expansion strategies, in stem cell transplant situations, in transplant purification, for disease prognosis, for gene therapy and immunotherapy. In this study, we analyzed the biological properties, induction differentiation, ex vivo expansion of cord blood CD133+ hematopoietic stem/progenitor cell, CD133-2 gene cloning, CD133-2 transgenic cell construction and preparation of anti-CD 133 mAb. The study laid a foundation for further researching and utilizing of CD133.Part I(1) Study on Biological Characteristics of Cord Blood CD133+ Hematopoietic Stem/progenitor CellStudies have shown CD133 may be more valuable HSPC surface sign than CD34. CD133 antigen is modeled as a unique 5-transmembrane molecule; especially the presence...